Generic and Biosimilar Pharmaceuticals Market - Global Outlook and Forecast 2021-2027

April 2021 | 101 pages | ID: G5AE48097629EN
Market Monitor Global

Abstracts

This report contains market size and forecasts of Generic and Biosimilar Pharmaceuticals in Global, including the following market information:

Global Generic and Biosimilar Pharmaceuticals Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global top five companies in 2020 (%)

The global Generic and Biosimilar Pharmaceuticals market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Generic and Biosimilar Pharmaceuticals companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Generic and Biosimilar Pharmaceuticals Market, By Type, 2016-2021, 2022-2027 ($ millions)

Global Generic and Biosimilar Pharmaceuticals Market Segment Percentages, By Type, 2020 (%)

• Monoclonal Antibodies
• Interferon
• Erythropoietin
• Insulin
• Vaccines
• Other

China Generic and Biosimilar Pharmaceuticals Market, By Application, 2016-2021, 2022-2027 ($ millions)

China Generic and Biosimilar Pharmaceuticals Market Segment Percentages, By Application, 2020 (%)

• Tumor
• Diabetes
• Cardiovascular
• Hemophilia
• Other

Global Generic and Biosimilar Pharmaceuticals Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions)

Global Generic and Biosimilar Pharmaceuticals Market Segment Percentages, By Region and Country, 2020 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Total Generic and Biosimilar Pharmaceuticals Market Competitors Revenues in Global, by Players 2016-2021 (Estimated), ($ millions)

Total Generic and Biosimilar Pharmaceuticals Market Competitors Revenues Share in Global, by Players 2020 (%)

Further, the report presents profiles of competitors in the market, including the following:

• Roche
• Amgen
• AbbVie
• Sanofi-Aventis
• Johnson & Johnson
• Pfizer
• Novo Nordisk
• Eli Lilly
• Novartis
• Merck
• 3sbio
• Changchun High Tech
• CP Guojian
• Biotech
• Gelgen
• Innovent
• Dong Bao
• Ganlee

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Generic and Biosimilar Pharmaceuticals Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Generic and Biosimilar Pharmaceuticals Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL GENERIC AND BIOSIMILAR PHARMACEUTICALS OVERALL MARKET SIZE

2.1 Global Generic and Biosimilar Pharmaceuticals Market Size: 2021 VS 2027
2.2 Global Generic and Biosimilar Pharmaceuticals Market Size, Prospects & Forecasts: 2016-2027
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Generic and Biosimilar Pharmaceuticals Players in Global Market
3.2 Top Global Generic and Biosimilar Pharmaceuticals Companies Ranked by Revenue
3.3 Global Generic and Biosimilar Pharmaceuticals Revenue by Companies
3.4 Top 3 and Top 5 Generic and Biosimilar Pharmaceuticals Companies in Global Market, by Revenue in 2020
3.5 Global Companies Generic and Biosimilar Pharmaceuticals Product Type
3.6 Tier 1, Tier 2 and Tier 3 Generic and Biosimilar Pharmaceuticals Players in Global Market
  3.6.1 List of Global Tier 1 Generic and Biosimilar Pharmaceuticals Companies
  3.6.2 List of Global Tier 2 and Tier 3 Generic and Biosimilar Pharmaceuticals Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 By Type - Global Generic and Biosimilar Pharmaceuticals Market Size Markets, 2021 & 2027
  4.1.2 Monoclonal Antibodies
  4.1.3 Interferon
  4.1.4 Erythropoietin
  4.1.5 Insulin
  4.1.6 Vaccines
  4.1.7 Other
4.2 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue & Forecasts
  4.2.1 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue, 2016-2021
  4.2.2 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue, 2022-2027
  4.2.3 By Type - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Generic and Biosimilar Pharmaceuticals Market Size, 2021 & 2027
  5.1.2 Tumor
  5.1.3 Diabetes
  5.1.4 Cardiovascular
  5.1.5 Hemophilia
  5.1.6 Other
5.2 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue & Forecasts
  5.2.1 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue, 2016-2021
  5.2.2 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue, 2022-2027
  5.2.3 By Application - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027

6 SIGHTS BY REGION

6.1 By Region - Global Generic and Biosimilar Pharmaceuticals Market Size, 2021 & 2027
6.2 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue & Forecasts
  6.2.1 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue, 2016-2021
  6.2.2 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue, 2022-2027
  6.2.3 By Region - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
6.3 North America
  6.3.1 By Country - North America Generic and Biosimilar Pharmaceuticals Revenue, 2016-2027
  6.3.2 US Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.3.3 Canada Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.3.4 Mexico Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
6.4 Europe
  6.4.1 By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue, 2016-2027
  6.4.2 Germany Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.4.3 France Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.4.4 U.K. Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.4.5 Italy Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.4.6 Russia Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.4.7 Nordic Countries Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.4.8 Benelux Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
6.5 Asia
  6.5.1 By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue, 2016-2027
  6.5.2 China Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.5.3 Japan Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.5.4 South Korea Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.5.5 Southeast Asia Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.5.6 India Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
6.6 South America
  6.6.1 By Country - South America Generic and Biosimilar Pharmaceuticals Revenue, 2016-2027
  6.6.2 Brazil Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.6.3 Argentina Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue, 2016-2027
  6.7.2 Turkey Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.7.3 Israel Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.7.4 Saudi Arabia Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027
  6.7.5 UAE Generic and Biosimilar Pharmaceuticals Market Size, 2016-2027

7 PLAYERS PROFILES

7.1 Roche
  7.1.1 Roche Corporate Summary
  7.1.2 Roche Business Overview
  7.1.3 Roche Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.1.4 Roche Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.1.5 Roche Key News
7.2 Amgen
  7.2.1 Amgen Corporate Summary
  7.2.2 Amgen Business Overview
  7.2.3 Amgen Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.2.4 Amgen Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.2.5 Amgen Key News
7.3 AbbVie
  7.3.1 AbbVie Corporate Summary
  7.3.2 AbbVie Business Overview
  7.3.3 AbbVie Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.3.4 AbbVie Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.3.5 AbbVie Key News
7.4 Sanofi-Aventis
  7.4.1 Sanofi-Aventis Corporate Summary
  7.4.2 Sanofi-Aventis Business Overview
  7.4.3 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.4.4 Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.4.5 Sanofi-Aventis Key News
7.5 Johnson & Johnson
  7.5.1 Johnson & Johnson Corporate Summary
  7.5.2 Johnson & Johnson Business Overview
  7.5.3 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.5.4 Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.5.5 Johnson & Johnson Key News
7.6 Pfizer
  7.6.1 Pfizer Corporate Summary
  7.6.2 Pfizer Business Overview
  7.6.3 Pfizer Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.6.4 Pfizer Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.6.5 Pfizer Key News
7.7 Novo Nordisk
  7.7.1 Novo Nordisk Corporate Summary
  7.7.2 Novo Nordisk Business Overview
  7.7.3 Novo Nordisk Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.4.4 Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.7.5 Novo Nordisk Key News
7.8 Eli Lilly
  7.8.1 Eli Lilly Corporate Summary
  7.8.2 Eli Lilly Business Overview
  7.8.3 Eli Lilly Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.8.4 Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.8.5 Eli Lilly Key News
7.9 Novartis
  7.9.1 Novartis Corporate Summary
  7.9.2 Novartis Business Overview
  7.9.3 Novartis Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.9.4 Novartis Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.9.5 Novartis Key News
7.10 Merck
  7.10.1 Merck Corporate Summary
  7.10.2 Merck Business Overview
  7.10.3 Merck Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.10.4 Merck Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.10.5 Merck Key News
7.11 3sbio
  7.11.1 3sbio Corporate Summary
  7.11.2 3sbio Business Overview
  7.11.3 3sbio Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.11.4 3sbio Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.11.5 3sbio Key News
7.12 Changchun High Tech
  7.12.1 Changchun High Tech Corporate Summary
  7.12.2 Changchun High Tech Business Overview
  7.12.3 Changchun High Tech Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.12.4 Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.12.5 Changchun High Tech Key News
7.13 CP Guojian
  7.13.1 CP Guojian Corporate Summary
  7.13.2 CP Guojian Business Overview
  7.13.3 CP Guojian Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.13.4 CP Guojian Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.13.5 CP Guojian Key News
7.14 Biotech
  7.14.1 Biotech Corporate Summary
  7.14.2 Biotech Business Overview
  7.14.3 Biotech Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.14.4 Biotech Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.14.5 Biotech Key News
7.15 Gelgen
  7.15.1 Gelgen Corporate Summary
  7.15.2 Gelgen Business Overview
  7.15.3 Gelgen Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.15.4 Gelgen Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.15.5 Gelgen Key News
7.16 Innovent
  7.16.1 Innovent Corporate Summary
  7.16.2 Innovent Business Overview
  7.16.3 Innovent Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.16.4 Innovent Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.16.5 Innovent Key News
7.17 Dong Bao
  7.17.1 Dong Bao Corporate Summary
  7.17.2 Dong Bao Business Overview
  7.17.3 Dong Bao Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.17.4 Dong Bao Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.17.5 Dong Bao Key News
7.18 Ganlee
  7.18.1 Ganlee Corporate Summary
  7.18.2 Ganlee Business Overview
  7.18.3 Ganlee Generic and Biosimilar Pharmaceuticals Major Product Offerings
  7.18.4 Ganlee Generic and Biosimilar Pharmaceuticals Revenue in Global (2016-2021)
  7.18.5 Ganlee Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Generic and Biosimilar Pharmaceuticals Market Opportunities & Trends in Global Market
Table 2. Generic and Biosimilar Pharmaceuticals Market Drivers in Global Market
Table 3. Generic and Biosimilar Pharmaceuticals Market Restraints in Global Market
Table 4. Key Players of Generic and Biosimilar Pharmaceuticals in Global Market
Table 5. Top Generic and Biosimilar Pharmaceuticals Players in Global Market, Ranking by Revenue (2019)
Table 6. Global Generic and Biosimilar Pharmaceuticals Revenue by Companies, (US$, Mn), 2016-2021
Table 7. Global Generic and Biosimilar Pharmaceuticals Revenue Share by Companies, 2016-2021
Table 8. Global Companies Generic and Biosimilar Pharmaceuticals Product Type
Table 9. List of Global Tier 1 Generic and Biosimilar Pharmaceuticals Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Generic and Biosimilar Pharmaceuticals Companies, Revenue (US$, Mn) in 2020 and Market Share
Table 11. By Type – Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2021 VS 2027
Table 12. By Type - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2016-2021
Table 13. By Type - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2022-2027
Table 14. By Application – Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2021 VS 2027
Table 15. By Application - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2016-2021
Table 16. By Application - Generic and Biosimilar Pharmaceuticals Revenue in Global (US$, Mn), 2022-2027
Table 17. By Region – Global Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2021 VS 2027
Table 18. By Region - Global Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), 2016-2021
Table 19. By Region - Global Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), 2022-2027
Table 20. By Country - North America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2021
Table 21. By Country - North America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022-2027
Table 22. By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2021
Table 23. By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022-2027
Table 24. By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2021
Table 25. By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022-2027
Table 26. By Country - South America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2021
Table 27. By Country - South America Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022-2027
Table 28. By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2021
Table 29. By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2022-2027
Table 30. Roche Corporate Summary
Table 31. Roche Generic and Biosimilar Pharmaceuticals Product Offerings
Table 32. Roche Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 33. Amgen Corporate Summary
Table 34. Amgen Generic and Biosimilar Pharmaceuticals Product Offerings
Table 35. Amgen Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 36. AbbVie Corporate Summary
Table 37. AbbVie Generic and Biosimilar Pharmaceuticals Product Offerings
Table 38. AbbVie Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 39. Sanofi-Aventis Corporate Summary
Table 40. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Product Offerings
Table 41. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Product Offerings
Table 44. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 45. Pfizer Corporate Summary
Table 46. Pfizer Generic and Biosimilar Pharmaceuticals Product Offerings
Table 47. Pfizer Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 48. Novo Nordisk Corporate Summary
Table 49. Novo Nordisk Generic and Biosimilar Pharmaceuticals Product Offerings
Table 50. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 51. Eli Lilly Corporate Summary
Table 52. Eli Lilly Generic and Biosimilar Pharmaceuticals Product Offerings
Table 53. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 54. Novartis Corporate Summary
Table 55. Novartis Generic and Biosimilar Pharmaceuticals Product Offerings
Table 56. Novartis Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 57. Merck Corporate Summary
Table 58. Merck Generic and Biosimilar Pharmaceuticals Product Offerings
Table 59. Merck Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 60. 3sbio Corporate Summary
Table 61. 3sbio Generic and Biosimilar Pharmaceuticals Product Offerings
Table 62. 3sbio Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 63. Changchun High Tech Corporate Summary
Table 64. Changchun High Tech Generic and Biosimilar Pharmaceuticals Product Offerings
Table 65. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 66. CP Guojian Corporate Summary
Table 67. CP Guojian Generic and Biosimilar Pharmaceuticals Product Offerings
Table 68. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 69. Biotech Corporate Summary
Table 70. Biotech Generic and Biosimilar Pharmaceuticals Product Offerings
Table 71. Biotech Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 72. Gelgen Corporate Summary
Table 73. Gelgen Generic and Biosimilar Pharmaceuticals Product Offerings
Table 74. Gelgen Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 75. Innovent Corporate Summary
Table 76. Innovent Generic and Biosimilar Pharmaceuticals Product Offerings
Table 77. Innovent Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 78. Dong Bao Corporate Summary
Table 79. Dong Bao Generic and Biosimilar Pharmaceuticals Product Offerings
Table 80. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)
Table 81. Ganlee Corporate Summary
Table 82. Ganlee Generic and Biosimilar Pharmaceuticals Product Offerings
Table 83. Ganlee Generic and Biosimilar Pharmaceuticals Revenue (US$, Mn), (2016-2021)

List Of Figures

LIST OF FIGURES

Figure 1. Generic and Biosimilar Pharmaceuticals Segment by Type
Figure 2. Generic and Biosimilar Pharmaceuticals Segment by Application
Figure 3. Global Generic and Biosimilar Pharmaceuticals Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Generic and Biosimilar Pharmaceuticals Market Size: 2021 VS 2027 (US$, Mn)
Figure 6. Global Generic and Biosimilar Pharmaceuticals Revenue, 2016-2027 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Generic and Biosimilar Pharmaceuticals Revenue in 2020
Figure 8. By Type - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 9. By Application - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 10. By Region - Global Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 11. By Country - North America Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 12. US Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 13. Canada Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 14. Mexico Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 15. By Country - Europe Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 16. Germany Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 17. France Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 18. U.K. Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 19. Italy Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 20. Russia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 21. Nordic Countries Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 22. Benelux Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 23. By Region - Asia Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 24. China Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 25. Japan Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 26. South Korea Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 27. Southeast Asia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 28. India Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 29. By Country - South America Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 30. Brazil Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 31. Argentina Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 32. By Country - Middle East & Africa Generic and Biosimilar Pharmaceuticals Revenue Market Share, 2016-2027
Figure 33. Turkey Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 34. Israel Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 35. Saudi Arabia Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 36. UAE Generic and Biosimilar Pharmaceuticals Revenue, (US$, Mn), 2016-2027
Figure 37. Roche Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 38. Amgen Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 39. AbbVie Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 40. Sanofi-Aventis Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 41. Johnson & Johnson Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 42. Pfizer Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 43. Novo Nordisk Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 44. Eli Lilly Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 45. Novartis Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 46. Merck Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 47. 3sbio Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 48. Changchun High Tech Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 49. CP Guojian Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 50. Biotech Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 51. Gelgen Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 52. Innovent Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)
Figure 53. Dong Bao Generic and Biosimilar Pharmaceuticals Revenue Year Over Year Growth (US$, Mn) & (2016-2021)